Media Update: New data at WMS 2023 reaffirm long-term efficacy of Nexviazyme® (avalglucosidase alfa) for the treatment of Pompe disease

https://ift.tt/KICSPgZ

from Sanofi - Aventis Groupe https://ift.tt/KNaeq0i
via IFTTT